FY2024 EPS Forecast for Sensus Healthcare Boosted by Analyst

Sensus Healthcare, Inc. (NASDAQ:SRTS) – Research analysts at HC Wainwright increased their FY2024 EPS estimates for shares of Sensus Healthcare in a report issued on Monday, November 18th. HC Wainwright analyst Y. Chen now expects that the company will post earnings per share of $0.42 for the year, up from their prior estimate of $0.36. HC Wainwright currently has a “Buy” rating and a $11.00 target price on the stock. The consensus estimate for Sensus Healthcare’s current full-year earnings is $0.38 per share. HC Wainwright also issued estimates for Sensus Healthcare’s Q4 2024 earnings at $0.11 EPS, Q1 2025 earnings at $0.14 EPS, Q2 2025 earnings at $0.10 EPS and FY2025 earnings at $0.52 EPS.

Separately, Maxim Group upped their target price on Sensus Healthcare from $12.00 to $14.00 and gave the company a “buy” rating in a report on Friday, November 15th.

Sensus Healthcare Price Performance

NASDAQ SRTS opened at $8.37 on Tuesday. The business has a 50 day moving average price of $6.42 and a 200 day moving average price of $6.00. The company has a market capitalization of $137.10 million, a P/E ratio of 14.75 and a beta of 1.04. Sensus Healthcare has a 1-year low of $2.02 and a 1-year high of $8.69.

Institutional Trading of Sensus Healthcare

Several large investors have recently modified their holdings of the business. Renaissance Technologies LLC lifted its stake in Sensus Healthcare by 34.4% in the 2nd quarter. Renaissance Technologies LLC now owns 391,534 shares of the company’s stock valued at $2,087,000 after buying an additional 100,294 shares in the last quarter. Dimensional Fund Advisors LP raised its holdings in shares of Sensus Healthcare by 128.0% in the second quarter. Dimensional Fund Advisors LP now owns 166,590 shares of the company’s stock worth $888,000 after acquiring an additional 93,511 shares during the last quarter. Geode Capital Management LLC lifted its position in shares of Sensus Healthcare by 8.5% in the third quarter. Geode Capital Management LLC now owns 146,404 shares of the company’s stock valued at $849,000 after acquiring an additional 11,525 shares in the last quarter. Sachetta LLC boosted its stake in shares of Sensus Healthcare by 12.9% during the second quarter. Sachetta LLC now owns 118,354 shares of the company’s stock valued at $631,000 after acquiring an additional 13,544 shares during the last quarter. Finally, Marshall Wace LLP increased its position in Sensus Healthcare by 152.4% during the 2nd quarter. Marshall Wace LLP now owns 77,387 shares of the company’s stock worth $412,000 after purchasing an additional 46,732 shares in the last quarter. 25.30% of the stock is currently owned by institutional investors and hedge funds.

Sensus Healthcare Company Profile

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.